Ryah Medtech, Northern Green Canada Pursue EU Medical Device Approval For Cannabis Inhaler

Data provider RYAH Medtech Inc. said Friday it has signed a distribution agreement with an EU GMP-certified producer of medical cannabis, Northern Green Canada Inc.

With this deal, the company — known for its dry herb inhaler — will reach consumers in German-speaking regions of Europe. 

There are two phases of the partnership: regulatory and commercial.

During the regulatory phase, both companies will work on obtaining EU Medical Device Registration approval for the RYAH dose-measuring inhale  and will present the basis for the inclusion of the planned products in German pharmacies.

During the commercial phase, the companies will create a commercial distribution strategy, and NGC will be an exclusive distributor of RYAH dose-controlled inhalers and cartridges, which will be filled with NGC’s sourced plant-based medicine, according to the press release. 

"This agreement with RYAH brings to our pipeline a high-value partnership with a medicinal focus and the potential to help a great number of patients in Germany and beyond," NGC Chief Executive Officer Lisa McCormack said in a statement.

"We are delighted to partner with RYAH, a pioneering specialty delivery device company with a strong team and we believe this alliance underscores our strong focus on and commitment to healthcare innovation.”

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsHealth CareMarketsGeneralCBDmedical cannabisNorthern Green CanadaRYAH Medtech Inc.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.